(Q40057989)

English

Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome

scientific article published on 8 May 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome (English)

1 reference

Europe PubMed Central

17 September 2017

2

1 reference

Europe PubMed Central

17 September 2017

Juan I Arostegui

object named as

Juan I Arostegui

1

0 references

author name string

Inmaculada Calvo

3

1 reference

Europe PubMed Central

17 September 2017

Angel Robles

4

1 reference

Europe PubMed Central

17 September 2017

Estibaliz Iglesias

5

1 reference

Europe PubMed Central

17 September 2017

Berta López-Montesinos

6

1 reference

Europe PubMed Central

17 September 2017

Romain Banchereau

7

1 reference

Europe PubMed Central

17 September 2017

Seunghee Hong

8

1 reference

Europe PubMed Central

17 September 2017

Yolandi Joubert

9

1 reference

Europe PubMed Central

17 September 2017

Guido Junge

10

1 reference

Europe PubMed Central

17 September 2017

Virginia Pascual

11

1 reference

Europe PubMed Central

17 September 2017

Jordi Yagüe

12

1 reference

Europe PubMed Central

17 September 2017

publication date

8 May 2017

1 reference

Europe PubMed Central

17 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

17 September 2017

69

1 reference

Europe PubMed Central

17 September 2017

8

1 reference

Europe PubMed Central

17 September 2017

1679-1688

1 reference

Europe PubMed Central

17 September 2017

Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Control of the innate immune response by the mevalonate pathway.

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

On-demand anakinra treatment is effective in mevalonate kinase deficiency

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Treatment of adult hyper-IgD syndrome with canakinumab.

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Quantitative gene set analysis generalized for repeated measures, confounder adjustment, and continuous covariates

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

1 reference

https://api.crossref.org/works/10.1002%2FART.40146

21 January 2018

Identifiers

10.1002/ART.40146

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40057989&oldid=1883394632"